Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation. 2004

Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

Although the role of the calcineurin-dependent pathway in the development of cardiac hypertrophy has been intensively studied, little is known of its role in vascular inflammatory diseases such as atherosclerosis and restenosis after angioplasty. To help elucidate the role of calcineurin in vascular inflammation, we infected cultured vascular smooth muscle cells (VSMCs) with an adenovirus construct expressing a constitutively active mutant of calcineurin, and examined its effect on the expression of monocyte chemoattractant protein-1 (MCP-1). We also examined the role of calcineurin in vivo using a transluminal wire injury model of the rat femoral artery. Forced activation of calcineurin significantly increased the expression of MCP-1 both at the transcriptional and protein levels. Angiotensin II (Ang II) also significantly stimulated MCP-1 expression, and this increase was significantly inhibited by cyclosporin A (CyA). Constitutive activation of calcineurin stabilized MCP-1 mRNA without enhancing MCP-1 promoter activity. In accordance with the results, Ang II-induced increase of MCP-1 promoter activity was not suppressed by CyA. Ang II stabilized MCP-1 mRNA, and this effect of Ang II was diminished by CyA. CyA suppressed MCP-1 expression in the femoral artery after the transluminal mechanical injury. CyA also inhibited macrophage infiltration and neointimal formation in the wire-injured femoral arteries. These results suggested that calcineurin mediates vascular inflammation via stimulation of MCP-1 expression in VSMCs and macrophage infiltration.

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell

Related Publications

Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
August 1995, Cytokine,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
June 1995, Endocrinology,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
March 2023, Current issues in molecular biology,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
February 1996, The Journal of surgical research,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
December 2001, Circulation research,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
July 2001, Hypertension (Dallas, Tex. : 1979),
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
August 1994, Cardiovascular research,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
February 2012, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
January 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Hiroshi Satonaka, and Etsu Suzuki, and Hiroaki Nishimatsu, and Shigeyoshi Oba, and Ryo Takeda, and Atsuo Goto, and Masao Omata, and Toshiro Fujita, and Ryozo Nagai, and Yasunobu Hirata
March 2008, Journal of applied physiology (Bethesda, Md. : 1985),
Copied contents to your clipboard!